Your browser doesn't support javascript.
loading
High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies.
Tagai, Kenji; Ono, Maiko; Kubota, Manabu; Kitamura, Soichiro; Takahata, Keisuke; Seki, Chie; Takado, Yuhei; Shinotoh, Hitoshi; Sano, Yasunori; Yamamoto, Yasuharu; Matsuoka, Kiwamu; Takuwa, Hiroyuki; Shimojo, Masafumi; Takahashi, Manami; Kawamura, Kazunori; Kikuchi, Tatsuya; Okada, Maki; Akiyama, Haruhiko; Suzuki, Hisaomi; Onaya, Mitsumoto; Takeda, Takahiro; Arai, Kimihito; Arai, Nobutaka; Araki, Nobuyuki; Saito, Yuko; Trojanowski, John Q; Lee, Virginia M Y; Mishra, Sushil K; Yamaguchi, Yoshiki; Kimura, Yasuyuki; Ichise, Masanori; Tomita, Yutaka; Zhang, Ming-Rong; Suhara, Tetsuya; Shigeta, Masahiro; Sahara, Naruhiko; Higuchi, Makoto; Shimada, Hitoshi.
Affiliation
  • Tagai K; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, The Jikei University Graduate School of Medicine, Tokyo 105-8461, Japan.
  • Ono M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Kubota M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
  • Kitamura S; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, Nara Medical University, Nara 634-8521, Japan.
  • Takahata K; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan.
  • Seki C; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Takado Y; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan. Electronic address: takado.yuhei@qst.go.jp.
  • Shinotoh H; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Neurology Clinic Chiba, Chiba 263-8555, Japan.
  • Sano Y; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan.
  • Yamamoto Y; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan.
  • Matsuoka K; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, Nara Medical University, Nara 634-8521, Japan.
  • Takuwa H; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Shimojo M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Takahashi M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Kawamura K; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Kikuchi T; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Okada M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Akiyama H; Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
  • Suzuki H; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan; National Hospital Organization Shimofusa Psychiatric Medical Center, Chiba
  • Onaya M; National Hospital Organization Shimofusa Psychiatric Medical Center, Chiba 266-0007, Japan.
  • Takeda T; Department of Neurology, National Hospital Organization Chibahigashi National Hospital, Chiba 260-8712, Japan.
  • Arai K; Department of Neurology, National Hospital Organization Chibahigashi National Hospital, Chiba 260-8712, Japan.
  • Arai N; Laboratory of Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
  • Araki N; Department of Neurology, National Hospital Organization Chibahigashi National Hospital, Chiba 260-8712, Japan.
  • Saito Y; National Center of Neurology and Pathology Brain Bank, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
  • Trojanowski JQ; Center for Neurodegenerative Disease Research and Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Lee VMY; Center for Neurodegenerative Disease Research and Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Mishra SK; Glycoscience Group, National University of Ireland, Galway H91 W2TY, Ireland.
  • Yamaguchi Y; Laboratory of Pharmaceutical Physical Chemistry, Tohoku Medical and Pharmaceutical University, Miyagi 981-8558, Japan.
  • Kimura Y; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology,
  • Ichise M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Tomita Y; Tomita Hospital, Aichi 444-3505, Japan.
  • Zhang MR; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Suhara T; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Department of Psychiatry, The Jikei University Graduate School of Medicine, Tokyo 105-8461, Japan.
  • Shigeta M; Department of Psychiatry, The Jikei University Graduate School of Medicine, Tokyo 105-8461, Japan.
  • Sahara N; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
  • Higuchi M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan. Electronic address: higuchi.makoto@qst.go.jp.
  • Shimada H; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Neuron ; 109(1): 42-58.e8, 2021 01 06.
Article in En | MEDLINE | ID: mdl-33125873
A panel of radiochemicals has enabled in vivo positron emission tomography (PET) of tau pathologies in Alzheimer's disease (AD), although sensitive detection of frontotemporal lobar degeneration (FTLD) tau inclusions has been unsuccessful. Here, we generated an imaging probe, PM-PBB3, for capturing diverse tau deposits. In vitro assays demonstrated the reactivity of this compound with tau pathologies in AD and FTLD. We could also utilize PM-PBB3 for optical/PET imaging of a living murine tauopathy model. A subsequent clinical PET study revealed increased binding of 18F-PM-PBB3 in diseased patients, reflecting cortical-dominant AD and subcortical-dominant progressive supranuclear palsy (PSP) tau topologies. Notably, the in vivo reactivity of 18F-PM-PBB3 with FTLD tau inclusion was strongly supported by neuropathological examinations of brains derived from Pick's disease, PSP, and corticobasal degeneration patients who underwent PET scans. Finally, visual inspection of 18F-PM-PBB3-PET images was indicated to facilitate individually based identification of diverse clinical phenotypes of FTLD on a neuropathological basis.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carbon Radioisotopes / Tauopathies / Benzothiazoles / Alzheimer Disease Limits: Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Neuron Journal subject: NEUROLOGIA Year: 2021 Document type: Article Affiliation country: Japan Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carbon Radioisotopes / Tauopathies / Benzothiazoles / Alzheimer Disease Limits: Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Neuron Journal subject: NEUROLOGIA Year: 2021 Document type: Article Affiliation country: Japan Country of publication: United States